Company intelligence / Profile preview

Tarus Therapeutics

New York*, New York, USAtryptherapeutics.com ↗

Ownership: Private
Employees: ~9
Development stage: Phase 1

Overview

Tarus developed highly potent and selective small molecule antagonists for the adenosine pathway, aiming to overcome immune suppression in solid tumors. Its lead programs targeted both single and dual blockade of A2A/A2B receptors. The most advanced program had reached Phase 1 prior to acquisition; subsequent development has continued under Portage Biotech/Cyncado Therapeutics with a focus on dual administration strategies for improved anti-tumor immunity

Therapeutic areas: Oncology
Modalities: Small molecules (specifically adenosine receptor antagonists targeting A2A and A2B receptors)
Industry: Biotech

Drug pipeline

4 assets

PORT-6

Phase 1

Indications: Solid tumors

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Tarus Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tarus Therapeutics.

Explore the full profile